Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

Journal:

Nature Communications

Published:

2025-11-05

DOI:

10.1038/s41467-025-64682-7

Affiliations:

5

Authors:

15

Go to article

Institutions	Authors	Share
Thomas Jefferson University (TJU), United States of America (USA)	10.000000 10.000000	0.67
Opna Bio - U.S.A., United States of America (USA)	3.000000	0.20
Albany Medical Center, United States of America (USA)	1.000000	0.07
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)	1.000000	0.07

Interested in Oncology and Carcinogenesis?